Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

2.03USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
209,580
52-wk High
$6.58
52-wk Low
$0.89

Chart for

About

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189... (more)
No analyst recommendations are available for .

Overall

Beta: 1.58
Market Cap(Mil.): $16.36
Shares Outstanding(Mil.): 12.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update

13 Nov 2017

BRIEF-Neuralstem Inc appoints two members to its board

* Neuralstem announces the appointment of two new members to the board of directors

25 Sep 2017

BRIEF-Neuralstem Inc gets two additional U.S. patents

* Neuralstem Inc - ‍been awarded two additional patents by United States Patent and Trademark Office​ Source text for Eikon: Further company coverage:

07 Sep 2017

BRIEF-Neuralstem reports Q2 loss per share $0.39

* Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update

08 Aug 2017

BRIEF-‍CVI investments reports a 8.3 pct passive stake in Neuralstem

* ‍CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing Source text: (http://bit.ly/2vbUBwE) Further company coverage:

07 Aug 2017

BRIEF-Neuralstem awarded grant by NIH to continue preclinical research into treatment for diabetic neuropathy

* Neuralstem awarded $~1mm grant by NIH to continue preclinical research into the potential of nsi-189 for treatment of diabetic neuropathy Source text for Eikon: Further company coverage:

02 Aug 2017

BRIEF-Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

* Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

25 Jul 2017

Earnings vs. Estimates